A Study to Evaluate the Efficacy and Safety of HR18042 Tablets in the Treatment of Postoperative Pain of Impacted Tooth.
A Multicenter,Randomized, Double-blind, Dose Ranging , Active- and Placebo-controlled, Parallel Groups, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HR18042 Tablets for the Treatment of Postoperative Pain of Impacted Tooth.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- West China Hospital of Stomatology Sichuan University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 to 75 years old.
- Subjects must have a plan of extraction of impacted tooth.
- Subjects with moderate to severe pain (VAS score ≥ 50mm).This must be measured within a maximum of 4 hours after the end of extraction of impacted tooth.
- weight at least 45kg,and no more than 100kg.
- If a female is of child-bearing potential, she must be using highly effective methods of contraception throughout the study.
- Willingness to comply with the study procedures and requirements.
- willing and able to provide written informed consent for this study.
Exclusion Criteria:
- any analgesic medication other than preoperative or intraoperative anaesthetic agents within 12h before taking trial medication medication
- a longacting NSAID within 4 days,or a shortacting NSAID within 1 days prior to dosing.
- any anti-depressive medication, selective serotonin reuptake inhibitors (SSRIs), diet pills et.al. with 30 days of study entry.
- Oral surgical site combined with infection.
- Severe cardiovascular and cerebrovascular diseases.
- Severe gastrointestinal disease.
- had a history of seizures or drug or alcohol abuse.
- uncontrolled hypertension.
- significant abnormal electrocardiogram
- significant abnormal laboratory value.
- Allergic to the study drug and ingredients.
- Pregnancy, lactation or recent Pregnant plan;
- Subjects who participated in a clinical research study involving an experimental drug before 30 days of study entry.
- other conditions unsuitable for participation in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: HR18042 100mg
|
Tablet, Dosing frequency: once daily, Route of administration: oral
Tablet,Dosing frequency: once daily, Route of administration: oral
|
|
Experimental: HR18042 125mg
|
Tablet, Dosing frequency: once daily, Route of administration: oral
Tablet,Dosing frequency: once daily, Route of administration: oral
|
|
Experimental: HR18042 200mg
|
Tablet, Dosing frequency: once daily, Route of administration: oral
Tablet,Dosing frequency: once daily, Route of administration: oral
|
|
Active Comparator: Tramadol hydrochloride ER 100mg
|
Tablet,Dosing frequency: once daily, Route of administration: oral
|
|
Placebo Comparator: Placebo to match HR18042 and Tramadol hydrochloride ER
|
Tablet,Dosing frequency: once daily, Route of administration: oral
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the Sum of Pain Intensity Differences(SPID)
Time Frame: 0-8hours
|
SPID is derived as the weighted Sum of Pain Intensity Differences (baseline pain - current pain), measured at different time points via the PI-VAS.
Time between two consecutive measurements will be used for weighting.
Larger values indicate larger pain relief.
|
0-8hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the Sum of Pain Intensity Differences(SPID)
Time Frame: 0-4hours
|
0-4hours
|
|
|
the Sum of Pain Intensity Differences(SPID)
Time Frame: 0-12hours
|
0-12hours
|
|
|
Pain Intensity Differences(PID)
Time Frame: 0-12hours
|
Include pain intensity differences(PIDs) from baseline at each time point.
measured at different time points via the PI-VAS.
|
0-12hours
|
|
Pain relief(PAR)
Time Frame: 0-12hours
|
pain relief (PAR) on a 5-point Likert scale (0, none, 1, a little, 2, some,3, a lot, 4, complete).
|
0-12hours
|
|
the Sum of Pain relief Differences(SPAR)
Time Frame: 0-4hours
|
SPAR is derived as the weighted Sum of Pain relief, measured at different time points via the 5-point Likert scale.
Time between two consecutive measurements will be used for weighting.
Larger values indicate larger pain relief.
|
0-4hours
|
|
the Sum of Pain relief Differences(SPAR)
Time Frame: 0-8hours
|
0-8hours
|
|
|
the Sum of Pain relief Differences(SPAR).
Time Frame: 0-12hours
|
0-12hours
|
|
|
Subject who reaches a 30% reduction in pain intensity from baseline
Time Frame: 4hours、8hours、12hours
|
4hours、8hours、12hours
|
|
|
Subject who reaches a 50% reduction in pain intensity from baseline
Time Frame: 4hours、8hours、12hours
|
4hours、8hours、12hours
|
|
|
time to perceptible pain relief
Time Frame: 0-12hours
|
0-12hours
|
|
|
time to meaningful pain relief
Time Frame: 0-12hours
|
Patients used one stopwatch to record the time to 'perceptible' PAR and another stopwatch for the time to'meaningful' PAR.Patients started timing upon intake of study medication and stopped one stopwatch at the onset of perceptible PAR and another upon achieving meaningful PAR.
|
0-12hours
|
|
Time to first use of rescue medication
Time Frame: 0-12hours
|
0-12hours
|
|
|
Proportion of subjects who take of at least 1 dose of rescue medication
Time Frame: 0-12hours
|
0-12hours
|
|
|
Subject's overall assessment of study medication
Time Frame: 12hours
|
Patients made an overall assessment of the study medication using a verbal rating scale (excellent, verygood, good, fair, poor).
|
12hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HR18042-201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.